VistaGen’s PALISADE-3 Trial Fails Primary Endpoint in SAD

The latest update is out from VistaGen Therapeutics ( (VTGN) ).

On December 17, 2025, Vistagen Therapeutics reported that its PALISADE-3 Phase 3 clinical trial of intranasal fasedienol for the acute treatment of social anxiety disorder failed to meet its primary endpoint, with no meaningful difference observed between fasedienol and placebo on the Subjective Units of Distress Scale, and no treatment difference on secondary endpoints, although the drug continued to show a favorable safety profile consistent with prior studies. The negative Phase 3 outcome represents a significant setback for the company’s lead social anxiety program and may prompt reassessment of its late-stage development strategy and timelines, even as the safety data could preserve some optionality for future clinical or partnering considerations.

The most recent analyst rating on (VTGN) stock is a Hold with a $0.72 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.

Spark’s Take on VTGN Stock

According to Spark, TipRanks’ AI Analyst, VTGN is a Neutral.

VistaGen Therapeutics’ overall stock score is primarily impacted by its challenging financial performance and bearish technical indicators. However, the positive outlook from recent corporate events and progress in clinical trials provides some optimism. The company’s strong equity position and strategic leadership changes are potential catalysts for future improvement.

To see Spark’s full report on VTGN stock, click here.

More about VistaGen Therapeutics

Vistagen Therapeutics, Inc. is a biopharmaceutical company developing drug candidates for psychiatric and neurological disorders, including intranasal treatments targeting conditions such as social anxiety disorder.

Average Trading Volume: 2,109,859

Technical Sentiment Signal: Strong Sell

Current Market Cap: $30.72M

For a thorough assessment of VTGN stock, go to TipRanks’ Stock Analysis page.